Connect with us


Cannabis data platform strikes deal with Europe’s largest CBD producer



The deal will help developers expand Efixii for commercial use

Medical cannabis data platform Global Cannabis Applications Corporation (GCAC) has signed a $0.4 million deal with Europe’s largest producer of CBD oil.

Chain-of-custody compliance and data platform, GCAC will supply QR Codes on the retail packaging of CBD Agrocasa.

GCAC’s Efixii platform attests to a CBD products’ life cycle, from seed to sale.

It is the only cannabis data platform in the world that acquires actual user-efficacy data on CBD consumption using its Efixii app – now available on Apple and Google’s Play Store.

The agreement is for the firms Efixii QR Codes to be applied to an initial retail rollout of 400 liters of CBD oil tinctures, containing approximately two million grams of cannabis.

Agrocasa focuses on producing the highest quality, authentic European CBD products using its Pharma-Grade EU GMP certified standard.

The company has the largest managed-grow operations of hemp inside Europe with a harvest capacity in excess of 4,000 ha. that produced approximately 24,000 liters of concentrated CBD oils in 2020.

“We are really looking forward to showcasing the power of Efixii’s truthful cannabis pre-consumption grow-data, coupled with Efixii’s post-consumption efficacy feedback-collection with Agrocasa’s retail products, said Brad Moore, CEO of GCAC.

“This $400k deal is for an initial run to enhance consumer confidence in Agrocasas’ products and add an amazing feedback-loop for Agrocasa to fine-tune their grows of local strains sourced from the EU Plant Variety database.”

Gabriel Luca, CEO of Agrocasa added: “The way in which Efixii uses blockchain to ensure the truth behind cultivators’ claims of CBD content, and the simplicity of its app-approach in capturing consumer feedback, is what drew us to license Efixii.

“We are HACCP compliant, Novelty Food registered and EU GMP certified and now, by adding consumer efficacy to the mix, Efixii could allow us to better plan our strain cultivations based on a strains efficacy in a given market vertical.”

Subject to a successful collection of efficacy data in the initial 400 liter run, both parties will work to expand the commercial use of Efixii across Agrocasa’s harvests in the future.

Sarah Sinclair is a respected cannabis journalist writing on subjects related to science, medicine, research, health and wellness. She is managing editor of Cannabis Health, the UK’s leading title covering medical cannabis and CBD, and sister titles, Cannabis Wealth and Psychedelic Health. Sarah has an NCTJ journalism qualification and an MA in Journalism from the University of Sunderland. Sarah has over six years experience working on newspapers, magazines and digital-first titles, the last two of which have been in the cannabis sector. She has also completed training through the Medical Cannabis Clinicians Society securing a certificate in Medical Cannabis Explained. She is a member of PLEA’s (Patient-Led Engagement for Access) advisory board, has hosted several webinars on cannabis and women's health and has moderated at industry events such as Cannabis Europa. Sarah Sinclair is the editor of Cannabis Health. Got a story? Email / Follow us on Twitter: @CannabisHNews / Instagram: @cannabishealthmag


Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2023 PP Intelligence Ltd.